Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive's Stephen Gunnion about the company’s new collaboration with Catalent, which reinforces its strategy to leverage the broad applicability of its lead molecule, certepetide, across multiple cancer types and treatment modalities. Dr Mazzo said the Catalent deal “really has, to a great extent, unlimited revenue potential,” pointing to the rapid growth of antibody-drug conjugates (ADCs) as a therapeutic class. He explained that the agreement with Catalent is non-exclusive for ADCs, giving Lisata the flexibility to engage with a range of partners across the oncology space. The CEO added that this marks the first time a third party has used a certepetide-related molecule in a conjugated format, validating Lisata’s hypothesis that the compound can be beneficial whether co-administered or conjugated. Lisata’s ongoing strategy is to expand certepetide’s use through partnerships that bring complementary technology or capital. Dr Mazzo emphasized that collaboration with an established company like Catalent is “a great step forward” as Lisata continues exploring additional partnership opportunities to maximize certepetide’s potential applications. For more interviews and company updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for future content. #LisataTherapeutics #DrDavidMazzo #Certepetide #Catalent #ADCTherapy #OncologyResearch #CancerTreatment #BiotechNews #PharmaPartnerships #ProactiveInvestors